<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>PRAVASTATIN</b></p>

<p><b>See also: HMG-CoA reductase inhibitors (statins)</b></p>

<p><b>From the French ANSM drug interactions document of September 2016, p. 181</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>PRAVASTATIN</b></p>

<p><b>RxNorm: 42463 </b></p>

<p><b>ATC: C10AA03</b></p></td>
<td valign="top"><p><b>CLARITHROMYCIN</b></p>

<p><b>RxNorm: 21212 </b></p>

<p><b>ATC: J01FA09 </b></p></td>
<td valign="top"><p>Increase of the plasma concentration of the pravastatin by the clarithromycin</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical and biological monitoring during the treatment with the antibiotic</p></td>
</tr>

<tr>
<td valign="top"><p><b>PRAVASTATIN</b></p>

<p><b>RxNorm: 42463 </b></p>

<p><b>ATC: C10AA03 </b></p></td>
<td valign="top"><p><b>ERYTHROMYCIN</b></p>

<p><b>RxNorm: 4053 </b></p>

<p><b>ATC:</b></p>

<p><b>D10AF02 J01FA01 S01AA17</b></p></td>
<td valign="top"><p>With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical and biological monitoring during the treatment with the antibiotic<b>.</b></p></td>
</tr>

</tbody>
</table>

